Menu

依普利酮2020价格

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

The name of the drug (Inspra) is still relatively unfamiliar to some domestic patients. It was a drug launched in the United States in 2002. It was first used to treat patients with hypertension. In 2003, it was approved by the FDA for the treatment of heart failure after acute myocardial infarction. As the first selective aldosterone receptor antagonist, eplerenone has played a positive role in the treatment of hypertension. The "China Guidelines for the Prevention and Treatment of Hypertension 2010" also proposed eplerenone as one of the main antihypertensive drugs.

Eplerenone has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction. It is safe and well tolerated and is a good alternative to spironolactone. Eplerenone (Inspra) is a selective aldosterone receptor antagonist that only acts on mineralocorticoid receptors and does not act on androgen and progesterone receptors. It has almost no sex hormone-related side effects of spironolactone.

The EPHESUS trial showed that for patients with left ventricular ejection fraction (LVEF) <40% and heart failure within 3 to 14 days after myocardial infarction, adding eplerenone (Inspra) to standard treatment can reduce all-cause death by 15%, primary combined endpoint events (cardiovascular death or hospitalization for cardiovascular events) by 17%, and sudden cardiac death by 21%.

It has been more than ten years since eplerenone was launched in 2020. We all know its effects, but what is its price?

It is understood that the price of the original drug eplerenone in the United States is relatively high, with specifications of 50mg-30 tablets/box, priced at about 124.09 US dollars. In comparison, the Indian version of eplerenone is a better choice for domestic patients.

The Indian version (Inspra) has a specification of 50mg*100 tablets and the price is around 500$. If it is inconvenient for patients to go abroad to purchase, they can consult our regular overseas medical consulting service company Medical Companion Travel for purchase details.

Recommended related hot articles: /newsDetail/73025.html

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。